Herceptin Conjugate Induces Tumor Cell Necrosis
Author Information
Author(s): Hu Jiemiao, Liu Xinli, Hughes Dennis, Esteva Francisco J., Liu Bolin, Chandra Joya, Li Shulin
Primary Institution: The University of Texas MD Anderson Cancer Center
Hypothesis
Can Herceptin conjugates promote direct tumor cell death and overcome tumor resistance to antibody treatment?
Conclusion
The Herceptin trimer conjugate can induce direct tumor cell death through programmed necrosis, even in Herceptin-resistant cells.
Supporting Evidence
- The Herceptin trimer was more effective than the dimer in inducing tumor cell death.
- EDC-Herceptin conjugates significantly inhibited survival of Her2-positive tumor cells.
- The study demonstrated that the EDC-Herceptin conjugate could overcome resistance in Herceptin-resistant cells.
Takeaway
This study shows that a special form of Herceptin can kill cancer cells directly, even those that usually resist treatment.
Methodology
The study used high-performance liquid chromatography to analyze Herceptin conjugates and assessed their effects on tumor cell lines through various assays.
Potential Biases
Potential bias in the selection of cell lines and experimental conditions.
Limitations
The study does not address the long-term effects of the Herceptin trimer in clinical settings.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website